ReviewJournal of translational autoimmunity2025
Epigenetic advances in rheumatic heart disease.
Review in Journal of translational autoimmunity, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Rheumatic heart disease (RHD), an autoimmune injury triggered by group A streptococcus (GAS) infection, exerts a significant pathological impact on the human heart. The pathogenesis of RHD is closely associated with abnormal epigenetic regulation, and primarily involves the four core epigenetic mechanisms: DNA methylation, histone modification, non-coding RNAs (ncRNAs), and chromatin remodeling. Currently, researches on RHD have shifted from focusing on late-stage diagnosis and treatment to investigating its multiple etiologies. Therefore, this article presents a systematic literature review aimed at reviewing the latest progress in the epigenetic research of RHD, providing in-depth elucidation of the interactions between RHD and these four core mechanisms, highlighting the value of potential biomarkers for the disease's early diagnosis and treatment, and outlining future research directions, including combined multi-omics analysis, minimally invasive interventional techniques, and gene chip-based approaches. This review aims to address the limitations of single-subject studies and small-sample cross-sectional surveys in epigenetic studies of RHD, thereby providing new strategies for disease prevention, control, and health management.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.